IPH5201

· Innate Pharma

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for IPH5201, covering 2025-05-16 to 2025-05-16. Get the full timeline:

Most recent: Clinical Trial Update: IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE) [Phase 2]